.
TAD disruption and aberrant expression as leukemia metabolic vulnerabilities for novel combination therapy tests in a drug screening platform (TOSCANINI)
Project/agreement No.
Project funding
1 503 294.00 EUR, of which RSU’s share is 153 738 EUR
Project manager
Project realization
01.12.2025. - 30.11.2028.
Aim
The aim of the TOSCANINI project is to identify specific metabolic vulnerabilities in leukemia that result from disrupted 3D genome organization (TADs) and abnormal gene expression, and to explore new personalized combination therapy strategies using a drug screening platform.
Description
TOSCANINI is a European collaborative research project focused on acute and chronic myeloid leukemia. It investigates how changes in the genome’s spatial structure, known as topologically associating domains (TADs), and altered gene activity contribute to disease development. By studying these mechanisms, the project aims to discover new weak points in leukemia cells that can be targeted with tailored drug combinations. RSU is involved in the collection and analysis of patient biological samples, contributing clinical expertise and molecular profiling to support personalized cancer treatment approaches.
Project team
- Prof. Sandra Lejniece
Expert Arturs Uzars
Expert Dārta Balode
